Compare Summit Therapeutics Inc (SMMT) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Wheaton Precious Metals Corp — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while Wheaton Precious Metals Corp trades at $134.91 (market cap $60.94B). The key difference: Wheaton Precious Metals Corp is far larger — about 5.1× Summit Therapeutics Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | WPM | |
|---|---|---|
Market Cap | $12.06B | $60.94B |
Sector | Health | Basic Materials |
52-Week High | $26.98 | $165.72 |
52-Week Low | $12.55 | $91.02 |
Enterprise Value | $11.39B | $62.82B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Wheaton Precious Metals (WPM) trades at $135.00, up 1.21% on the day, with a bullish technical signal supported by moving averages. The company reported record first-half 2026 results, with Q2 earnings of $1.19 per share beating estimates, driven by higher metal prices and sales volumes. Strong profitability is evident with a net income margin of 64.66% and robust cash flow from operations of $1.90 billion in 2025. Analyst consensus is strongly positive with a buy rating from 80% of covering firms and a price target of $161.75.
The outlook remains favorable given sustained high precious metal prices and operational execution, though elevated valuation multiples and potential commodity price volatility present risks. Upside is supported by consistent earnings beats and institutional confidence, but investors should weigh the stock's premium pricing against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
